公开(公告)号：US20210363259A1

公开(公告)日：2021-11-25

申请号：US16640422

申请日：2018-08-22

Applicant: Biogen MA Inc.

Inventor： Tia Brie Estey ,  Geetha Govindan ,  Sonal Saluja ,  Kapil Gupta ,  Margaret McGrath

IPC: C07K16/28 ,  A61K47/18 ,  A61K47/26 ,  A61K31/4418 ,  A61K31/496 ,  A61K47/12 ,  A61K47/20

Abstract: Formulations and dosage regimens of an anti-αvβ6 antibody or αvβ6-binding fragment thereof are provided. These formulations find use in the treatment of e.g., fibrosis (e.g., idiopathic pulmonary fibrosis), acute lung injury, and acute kidney injury.

公开(公告)号：US20180264112A1

公开(公告)日：2018-09-20

申请号：US15543653

申请日：2016-01-15

Applicant: Biogen MA Inc.

Inventor： Mark Krebs ,  Adnan Zunic ,  Tia Estey ,  Shantanu Sule ,  Margaret McGrath ,  Lori Karpes ,  Yana Kravets

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  A61K9/00 ,  A61K47/22

CPC classification number: A61K39/39591 ,  A61K9/0019 ,  A61K47/12 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/54 ,  C07K16/2878 ,  C07K2317/56 ,  C07K2317/565

Abstract: Provided herein, in some aspects, are low viscosity, low aggregation propensity, high anti-CD40 antibody concentration formulations.